Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
The US agency maintains that Glatiramer acetate is an approved medicine to treat patients with relapsing forms of MS. (Image Credits: Reuters) The U.S. Food and Drug Administration (FDA ...
The US Food and Drug Administration (FDA) has added a boxed warning to the label of multiple sclerosis drug glatiramer acetate about the risk of anaphylaxis. From December 1996 through May 2024 ...
Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals and patients with multiple sclerosis that treatment with ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to ...
The following is a summary of “Cost–consequence analysis of early vs. delayed natalizumab use in highly active ...
This study confirms that beta-interferons and glatiramer acetate are safe for use during early pregnancy. In addition, fumarate is likely a safe treatment option during pregnancy, and natalizumab ...
Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden ...
GlobalData on MSN18d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesThe US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...
It’s not known whether Copaxone (glatiramer acetate) is safe to use while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you should use the ...
Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...
GlobalData on MSN14d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback